In this Issue
A look at some of the therapeutic and pharmacologic treatment approaches used outside of the OR.
MEDICAL EDITORS’ PAGE
By Allen C. Ho, MD, and Robert L. Avery, MD
BUSINESS OF RETINA
PA Avenue Updates
How to make this widely used EHR system more efficient for high-volume vitreoretinal surgeons.
By William J. Foster, MD, PhD, and David Fleece, MD
Innovations in Retina
Early detection may allow treatment and possible reversal. Part 1 of a 2-part series.
By Aron Shapiro
Tips for newly graduated fellows.
By Murtaza Adam, MD
Coding for Retina
These coding tips and examples can help minimize common problems related to claim denials.
By Riva Lee Asbell
Concept of ILM flap or patch for use in challenging cases.
By Brian C. Joondeph, MD, MPS
Surgery to remove these devices must involve caution due to risk of complications.
By Niels Crama, MD
New pharmacologic treatment options are urgently needed.
By Steven Yeh, MD, and Jessica G. Shantha, MD
SPECIAL FOCUS: OCULAR ONCOLOGY
Play your cards right and make the best bet for tumor diagnosis.
By Carol L. Shields, MD; Kareem Sioufi, MD; Timothy Fuller, MD; Timothy Higgins, BS; Sandor R. Ferenczy, CRA; and Jerry A. Shields, MD
History, technique, and update on outcomes.
By Ryan S. Kim, BA; Mark J. Dannenbaum, MD; and Amy C. Schefler, MD
COVER FOCUS: THE NONSURGICAL SIDE OF RETINA
Shedding light on a new breed of clinicians.
By Jordana G. Fein, MD, MS, and Heeral R. Shah, MD
Study results suggest this class of drug has vitreolytic activity and a longer duration of effect than current treatments.
By Victor H. Gonzalez, MD
Laser still plays a prominent part in managing retinal pathologies, and innovations in laser delivery suggest potential areas where indications might be expanded.
By Baruch Kuppermann, MD, PhD
WHAT’S NEW ON THE ANTI-PDGF FRONT?
The potential for this proposed treatment option could be significant for many patients and their caregivers.
By Carl C. Awh, MD
Could an anti-PDGF drug work with an anti-VEGF agent to provide better antiangiogenic effect than anti-VEGF monotherapy?
By Jeffrey S. Heier, MD
Could the combination of an anti-VEGF agent and an anti-PDGF drug solve some of the issues seen with anti-VEGF monotherapy? Trial data may soon tell.
By Glenn J. Jaffe, MD
By the staff of Retina Today
Ehsan Rahimy, MD, is a Surgical and Medical Vitreoretinal Specialist at the Palo Alto Medical Foundation in Palo Alto, Calif.